Healthcare Industry News: neuromodulation
News Release - May 14, 2008
St. Jude Medical Announces Launch of New Circular Mapping CatheterST. PAUL, Minn.--(HSMN NewsFeed)--St. Jude Medical, Inc. (NYSE:STJ ) today announced the U.S. launch of the Reflexion Spiral X™ variable radius mapping catheter at Heart Rhythm 2008. This new catheter will provide physicians with greater maneuverability, stability and control when used in the left atrium for the mapping of abnormal atrial heart arrhythmias, including Atrial Fibrillation (AF).
Circular mapping catheters are designed to measure electrical activity at the opening of the pulmonary veins, which often are the sites where AF originates in the left atrium. The new Reflexion Spiral X catheter is the first variable radius, circular mapping catheter that features two-way 180-degree deflection to provide greater reach and versatility in challenging anatomic situations. The increased versatility provided by the bi-directional 180-degree steering lessens the risk that the physician would not be able to access an area of the chamber to capture the electrical information properly.
The new decapolar (10 electrode) catheter also features the ComfortGrip™ handle to facilitate one-handed control of the catheter (to improve ease of use) and modifications to the catheter shaft and circular hoop to provide excellent stability.
“As a pioneer in the atrial fibrillation field, we’re committed to improving the effectiveness of diagnosing and treating AF, and to helping physicians improve patient outcomes,” said Jane J. Song, president of the St. Jude Medical Atrial Fibrillation Division.
Heart Rhythm 2008 takes place May 14-17 at the Moscone Convention Center in San Francisco. The meeting is the most comprehensive educational event on heart rhythm disorders, offering 250 educational opportunities in multiple formats. The world’s most renowned scientists and physicians will present a wide range of heart rhythm topics including advances in statins, cardiac resynchronization therapy, catheter ablation, cardiac pacing and heart failure and the latest technology, including state-of-the-art pacemakers and defibrillators. www.HRSonline.org
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting the most control possible into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide and has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. For more information, please visit www.sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K filed on February 27, 2008. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Source: St. Jude Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.